NasdaqGS:ABCLLife Sciences
Will AbCellera’s (ABCL) Bruker Patent Settlement and Royalties Shift Its Long-Term Revenue Narrative?
On December 18, 2025, AbCellera Biologics announced it had resolved its global patent litigation with Bruker Corporation through a settlement and patent license agreement, under which Bruker will pay AbCellera US$36 million upfront plus ongoing royalties on sales of its Beacon Optofluidic platform products for the life of the licensed patents.
This deal not only removes legal uncertainty but also adds a new royalty stream that could complement AbCellera’s transition toward downstream,...